Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Neuromuscular
At what point do you consider weaning steroids or immuno-modulating agents in patients with Myasthenia Gravis?
How long do you monitor for clinical stability?
Related Questions
How do you track objective clinical response to treatment in CIDP?
How do you use muscle MRI in the diagnosis and management of muscular dystrophies?
In which clinical scenarios do you find medial and lateral plantar sensory or mixed nerve conduction studies to be valuable?
Would you add immunosuppression in ocular myasthenia gravis patients who are symptomatically well-controlled on pyridostigmine?
How do you approach managing nausea and GI side effects when initiating methotrexate?
Do you perform EMG and repetitive nerve stimulation in patients with ocular myasthenia gravis, particularly those who are AChR-positive, to assess for electrophysiological evidence of generalized disease?
How do you reconcile the benefits of high glycemic load to slow ALS disease progression with previous data on the increased risk for ALS associated with diabetes mellitus?
How frequently do you re-evaluate AChR and MuSK antibodies in patients with clinical and electrodiagnostic evidence of seronegative myasthenia gravis?
When do you test for myasthenia antibodies beyond AChR and MuSK?
When would you refer patients with Parsonage-Turner syndrome for surgical treatment?